Drug reference

Etodolac

NSAID · Anti-inflammatory, Analgesic

NSAIDAnti-inflammatory, Analgesic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AminoglycosideSevereTextbookKDT 7e · p746
AminoglycosidesSevereTextbookKDT 7e
AnticoagulantsSevereTextbookKDT 7e
CorticosteroidsSevereTextbookKDT 7e

Mechanism

Etodolac is a traditional nonsteroidal anti-inflammatory drug (tNSAID) that acts as a competitive, reversible inhibitor of cyclooxygenase (COX) enzymes. It primarily inhibits both COX-1 and COX-2 enzymes, with some degree of selectivity for COX-2. This inhibition reduces the production of prostaglandins, which are mediators of pain and inflammation.

Indications

Pain and inflammation in rheumatoid arthritisPain and inflammation in osteoarthritisJuvenile arthritisPostoperative analgesiaOsteoarthritisRheumatoid arthritisMild-to-moderate painacute musculoskeletal pain

Dosing

Adult: BY MOUTH USING MODIFIED-RELEASE MEDICINES: 600 mg once daily
Pediatric: >6 years (extended release): 400 mg/day (20–30 kg); add 200 mg/15 kg more weight

Pharmacokinetics

Onset

Peak plasma concentration (Cp) 1 h

Duration

Postoperative analgesia lasts for 6–8 hours.

Half-life

7 h

Protein binding

99%

Metabolism

Hepatic metabolism

Contraindications

Active gastro-intestinal bleeding
Active gastro-intestinal ulceration
History of gastro-intestinal bleeding related to previous NSAID therapy
History of gastro-intestinal perforation related to previous NSAID therapy
History of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
History of recurrent gastro-intestinal ulceration (two or more distinct episodes)
Severe heart failure

Side effects

Common

ConstipationDiarrhoeaDizzinessDrowsinessGastrointestinal discomfortGastrointestinal disordersHeadacheAdverse effects similar to sulindac, but ~half as frequent.About 5% of patients discontinue treatment because of GI side effectsRashesCNS effectsabdominal pain

Serious

Agranulocytosis
Angioedema
Aplastic anaemia
Asthenia
Asthma
Bilirubinuria
Bronchospasm
Chills
Confusion
Crohn’s disease aggravated
Depression
Dyspnoea
Fever
Haemolytic anaemia
Haemorrhage
Hallucination
Heart failure

Pregnancy & lactation

Pregnancy

Drug interactions

Aminoglycoside

Severe

Textbook

Increased risk of nephrotoxicity.

Avoid concurrent use.

Source: KDT 7e · p746

Aminoglycosides

Severe

Textbook

Increased aminoglycoside levels and potential toxicity.

Monitor aminoglycoside levels and renal function; adjust dosage as needed.

Source: KDT 7e

Anticoagulants

Severe

Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider alternative analgesics or gastroprotective agents.

Source: KDT 7e

Corticosteroids

Severe

Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents.

Source: KDT 7e

Dapoxetine

Severe

Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Enalaprilat

Severe

Textbook

Reduced effectiveness of ACE inhibitors. Marked hyperkalemia, potentially leading to cardiac arrhythmia.

Use with caution, especially in the elderly and in patients with hypertension, diabetes mellitus, or ischemic heart disease.

Source: G&G 14e · p836

Escitalopram + Clonazepam

Severe

Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Glucocorticoids

Severe

Textbook

Increased risk of gastritis, ulcer formation, and gastrointestinal bleeding. Glucocorticoids can also mask the symptoms of serious gastrointestinal disease, increasing the risk of perforated sigmoid diverticular abscesses.

Not explicitly stated, but implies caution and awareness of increased risk.

Source: G&G 14e · p1013

Quinolones

Severe

Textbook

Enhanced neurological adverse effects.

Use with caution, especially in patients with a history of epilepsy.

Source: G&G 14e · p1144

Acalabrutinib

Severe

Database

Drug interaction classified as: synergy